UCB - Sustainable Growth, Now and into the Future

Further facts and figures
29 July 2021
HY results call
Disclaimer & Safe Harbor

Forward-Looking Statements

This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. There can be no guarantee that the investigational or approved products potentially described in this presentation will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. There can be no guarantee that the investigational or approved products potentially described in this presentation will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation, and do not reflect any potential impacts from the evolving COVID-19 pandemic, unless indicated otherwise. UCB continues to follow the development diligently to assess the financial significance of this pandemic to UCB. Information contained in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

UCB expressly disclaims any obligation to update any forward-looking statements in this presentation, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this presentation and the Integrated Annual Report or Half Year Report, the information included in the Report shall prevail.
UCB Story – since 1928

Continuous Adaptation to the Changing Ecosystem

1928
Emmanuel Janssen established Union Chimique Belge (UCB) in Brussels (Belgium), primarily focusing on industrial chemicals.

1928 - Production primary care products (calcium, vitamins, insulin, etc.) during World War II

1928 - Emmanuel Janssen established Union Chimique Belge (UCB) in Brussels (Belgium), primarily focusing on industrial chemicals.

1970’s - Development of a European network through acquisitions in France, Germany, Italy, Spain and the U.K.

80’s
Globalization with acquisitions in the U.S., Korea, Thailand and Japan

80’s - Stronger focus on research, resulting in the discovery in 1954 of one of the world’s first tranquillizers, Atarax®

1987
1987 - Focus on biopharmaceuticals, a combination of large, antibody based molecules and small, chemically-derived molecules

1987 - Acquisition of Celltech Group Ltd., a leading British biotechnology company

2000
2000 - Focus on biopharmaceuticals, a combination of large, antibody based molecules and small, chemically-derived molecules

2000 - Acquisition of Schwarz Pharma AG, based in Germany, bringing complementary therapeutic and geographic focus

2004
2004 - Focus on biopharmaceuticals, a combination of large, antibody based molecules and small, chemically-derived molecules

2004 - Divestiture of non-core business, starting with the films and chemical divisions, followed by primary care products

2008
2008 - Globalization with acquisitions in the U.S., Korea, Thailand and Japan

2008 - EVENITY™ (romosozumab-agng)

2019
2019 - Globalization with acquisitions in the U.S., Korea, Thailand and Japan

2019 - NAYZILAM® (midazolam) nasal spray

2021 HY - 3
UCB’s Patient Value Strategy

Sustained Company Growth – Superior Shareholder Value

Our ambition is to be the patient preferred biopharma leader, creating patient value for specific populations through unique outcomes, the best experience and improving as many of these lives as possible.

We want to be present and impact specific patient populations by 2025.

We bring Cimzia®, Vimpat®, Keppra®, Briviact®, Neupro®, Nayzilam® & Evenity® to ≈ 3.5 million patients*

Focused on R&D:
We invest more than 29%* of revenue in R&D – above industry average

We commit to reducing our ecological footprint

We reached in 2020 € 5.3 billion revenue € 1.4 billion adjusted EBITDA, both growing for the 7th year in a row

* Data at 31 December 2020
Our Core Products

Key Information

<table>
<thead>
<tr>
<th>Cimzia®</th>
<th>Vimpat®</th>
<th>Keppra®</th>
<th>Briviact®</th>
<th>Neupro®</th>
</tr>
</thead>
</table>
| • Crohn’s disease  
• Rheumatoid arthritis  
• Psoriatic arthritis  
• Axial spondyloarthritis  
• Psoriasis | • Epilepsy POS  
• Epilepsy PGTCS | • Epilepsy POS  
• Epilepsy PGTCS  
• Epilepsy myoclonic seizures | Epilepsy POS  
• Adj. therapy  
• Monotherapy (U.S.)  
• Pediatric | Epilepsy POS  
• Parkinson’s disease  
• Restless legs syndrome |

> 151,000 patients, across 58 countries*  
> 734,000 patients, across 52 countries*  
≈ 2.1 million patients, across the world*  
> 126,000 patients, across 40 countries*  
> 374,000 patients, across 43 countries*

**Astellas** (Japan - 2012)  
**Cinkate** (China – 2019)  
**Daiichi Sankyo** (Japan - 2014)  
**Otsuka** (Japan – 2002-2020)  
**Otsuka** (Japan – 2008-2020)

| 2024 (U.S. & EU)  
2026 (Japan) | 2022 (U.S. & EU)  
2024 (Japan) | 2008 (U.S.)  
2010 (EU)  
2020 (Japan) | 2026 (U.S. & EU) | 2021 (U.S. & EU)  
2024 (Japan)  
2030 Several reformulation patents (U.S. & EU) |

* Data at 31 December 2020  
POS: partial onset seizures, also known as focal seizures  
PGTCS: primary generalized tonic-clonic seizures
## Strong Underlying Net Sales Growth

Resilient product portfolio, change of E KEPPRA® distribution model & new launches

### 2021 HY Net Sales

€ 2 651 Million
(+6%; +11% CER)

- **Epilepsy**
  - CIMZIA® € 873 M (+4%; +11% CER) Driven by new patient populations
  - VIMPAT® € 735 M (+2%; +9% CER) Strong growth at CER in all markets
  - KEPPRA® € 485 M (+16%; +23% CER) Driven by in-market net sales booking in Japan
  - BRIVIACT® € 166 M (+15%; +24% CER) Reaching more and more patients
  - NEUPRO® € 158 M (+1%; +5% CER) Strong growth in international markets
  - NAYZILAM® € 21 M (>100%; >100% CER) Launched December 2019
  - EVENITY® € 4 M (>100%; >100% CER) Europe, Launched March 2020
- **Established Brands (EB)** € 168 M (-18%; -15% CER)

---

CER = constant exchange rates

Net sales include € 40 million designated hedges reclassified to net sales, adjusted for E Keppra change of distribution model + 7% CER
Cimzia®

Driven by New Patient Populations

For patients (including women of child-bearing age) living with
- Rheumatoid arthritis
- Psoriatic arthritis
- Psoriasis
- Axial spondyloarthritis
- Crohn’s disease (U.S.)*

* partnered with Ferring

1 Loss of exclusivity dates are indicative.
2 Numbers may not add due to rounding

Peak sales guidance > € 2 billion by 2024
Loss of exclusivity
- 2024 U.S. & EU
- 2026 Japan

Global sales
U.S.
Europe
In’tl markets

Net sales in € million, FY numbers


1 10 75 198 312 467 594 797 1,083 1,304 1,424 1,446 1,712 1,799 1,174

Net sales in € million, FY numbers


1 10 75 198 312 467 594 797 1,083 1,304 1,424 1,446 1,712 1,799 1,174

Net sales in € million, FY numbers


1 10 75 198 312 467 594 797 1,083 1,304 1,424 1,446 1,712 1,799 1,174
Cimzia® In-Market Performance

**U.S.**

**Cimzia® vs. Rheumatology Market Growth**

- Anti TNF: 12.2%
- Biologics: 13.7%
- Cimzia®: 12.8%

**Cimzia® Rheumatology R3M Patient Share**

- April 20: 8.0%
- July 20: 8.5%
- October 20: 9.0%
- January 21: 9.5%
- April 21: 10.0%

Source: IQVIA Source of Business Report

**Europe**

**Cimzia® vs. Rheumatology Market Growth**

- Anti TNF: 7.6%
- Biologics: 8.0%
- Cimzia®: 8.5%

**Cimzia® Rheumatology R3M Patient Share**

- May 20: 7.0%
- August 20: 7.5%
- November 20: 8.0%
- February 21: 8.5%
- May 21: 9.0%

Source: IMS MIDAS

**Japan**

**Cimzia® vs. RA Market Growth**

- Anti TNF: 8.6%
- Biologics: 11.0%
- Cimzia®: 12.4%

**Cimzia® RA R3M Patient Share**

- May 20: 3.0%
- August 20: 3.5%
- November 20: 4.0%
- February 21: 4.5%
- May 21: 5.0%

Source: IMS MIDAS

1 In-market growth is calculated for MAT period: U.S.: MAT Apr 2021 vs. MAT Apr 2020 / Europe: MAT May 2021 vs MAT May 2020 | Japan: MAT May 2021 vs. May 2020 (patients, all channels)
2 Market share is calculated for R3M period
Strong, Sustainable Growth in All Markets

For patients living with
- Epilepsy - POS
- Epilepsy - PGTCS
- Adults, adolescents and children from 4 years of age (EU, U.S. & Japan)

Peak sales guidance > € 1.5 billion by 2022

Loss of exclusivity¹
- **2022** U.S. & EU
- **2024** Japan

¹ Loss of exclusivity dates are indicative.
² Numbers may not add due to rounding

POS: Partial-onset seizures, also known as focal seizures; PGTCS: Primary Generalized Tonic-Clonic Seizures
**Vimpat® In-Market Performance**

**U.S.**

Vimpat® vs. AED Market Growth (TRx)

Vimpat® R3M TRx Share: 3.8%

AED Market: 0.0%
Vimpat®: 2.6%

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

**Europe**

Vimpat® vs. AED Market Growth (TDx)

Vimpat® R3M TDx Share: 5.0%

AED Market: -1.8%
Vimpat®: 11.2%

Source data EU: IMS MIDAS - In-Market KPI's are based on TDx

**Japan**

Vimpat® vs. AED Market Growth

Vimpat® R3M TDx Share: 4.3%

AED Market: -0.8%
Vimpat®: +22.9%

Source data JP: IMS MIDAS - In-market KPI's are based on TDx

---

**AED market:** All molecules in ATC3= N3A + Phenobarbital in N5B.
In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage.
In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
Keppra®

Mature, Established Brand

For patients living with
• Epilepsy - POS
• Epilepsy - PGTCS
• Epilepsy myoclonic seizures

Peak sales: € 1.3 billion (2008)
Loss of exclusivity
• 2008 U.S.
• 2010 EU
• 2020 Japan

Global sales
U.S.
Europe
In'tl markets

Net sales in € million, FY numbers

1 Numbers may not add due to rounding

POS: Partial-onset seizures, also known as focal seizures; PGTCS: Primary Generalized Tonic-Clonic Seizures
Keppra® In-Market Performance

**U.S.**

Keppra® vs. AED Market Growth (TRx)

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® vs. AED Market Growth (TRx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0.0%</td>
</tr>
<tr>
<td>May-21</td>
<td>+15.1%</td>
</tr>
</tbody>
</table>

Keppra® vs. AED Market Growth (TDx)

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® vs. AED Market Growth (TDx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-2%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>-4%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0%</td>
</tr>
<tr>
<td>May-21</td>
<td>+6%</td>
</tr>
</tbody>
</table>

Keppra® – R3M TRx Share

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® – R3M TRx Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-15.1%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0.4%</td>
</tr>
<tr>
<td>May-21</td>
<td>10.6%</td>
</tr>
</tbody>
</table>

Keppra® – R3M TDx Share

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® – R3M TDx Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Mar-21</td>
<td>10.6%</td>
</tr>
</tbody>
</table>

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

**Europe**

Keppra® vs. AED Market Growth (TRx)

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® vs. AED Market Growth (TRx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0%</td>
</tr>
<tr>
<td>May-21</td>
<td>6.6%</td>
</tr>
</tbody>
</table>

Keppra® vs. AED Market Growth (TDx)

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® vs. AED Market Growth (TDx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-2%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>-4%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0%</td>
</tr>
<tr>
<td>May-21</td>
<td>+6%</td>
</tr>
</tbody>
</table>

Keppra® – R3M TRx Share

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® – R3M TRx Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-15.1%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0.4%</td>
</tr>
<tr>
<td>May-21</td>
<td>10.6%</td>
</tr>
</tbody>
</table>

Keppra® – R3M TDx Share

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® – R3M TDx Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-2%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>-4%</td>
</tr>
<tr>
<td>Mar-21</td>
<td>10.6%</td>
</tr>
</tbody>
</table>

Source data EU: IMS MIDAS - In-Market KPI's are based on TDx

**Japan**

Keppra® vs. AED Market Growth (TRx)

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® vs. AED Market Growth (TRx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0%</td>
</tr>
<tr>
<td>May-21</td>
<td>6.6%</td>
</tr>
</tbody>
</table>

Keppra® vs. AED Market Growth (TDx)

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® vs. AED Market Growth (TDx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-2%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>-4%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0%</td>
</tr>
<tr>
<td>May-21</td>
<td>+6%</td>
</tr>
</tbody>
</table>

Keppra® – R3M TRx Share

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® – R3M TRx Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-15.1%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Feb-21</td>
<td>0.4%</td>
</tr>
<tr>
<td>May-21</td>
<td>10.6%</td>
</tr>
</tbody>
</table>

Keppra® – R3M TDx Share

<table>
<thead>
<tr>
<th>Month</th>
<th>Keppra® – R3M TDx Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>May-20</td>
<td>-2%</td>
</tr>
<tr>
<td>Aug-20</td>
<td>0%</td>
</tr>
<tr>
<td>Nov-20</td>
<td>-4%</td>
</tr>
<tr>
<td>Mar-21</td>
<td>10.6%</td>
</tr>
</tbody>
</table>

Source data JP: IMS MIDAS - In-market KPI's are based on TDx

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B.
In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage.
In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
Available to More and More Patients

For patients living with
• Epilepsy - POS
• Adults, adolescents and children from 4 years of age (EU & U.S.)

Briviact®

Peak sales: € 600 million (2026)
Loss of exclusivity¹
• 2026 U.S. & EU
• Not yet available in Japan

POS: Partial-onset seizures, also known as focal seizures

¹ Loss of exclusivity dates are indicative.
² Numbers may not add due to rounding
Briviact® In-Market Performance

**U.S.**

Briviact® vs. AED Market Growth (TRx)

- AED Market: 0.0%
- Briviact®: 21.9%

Briviact® – R3M TRx Share

- May-20: 0.50%
- Aug-20: 0.00%
- Nov-20: 0.20%
- Feb-21: 0.40%
- May-21: 0.60%

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

**Europe**

Briviact® vs. AED Market Growth (TDx)

- AED Market: -1.8%
- Briviact®: 32.1%

Briviact® – R3M TDx Share

- May-20: 1.13%
- Aug-20: 0.3%
- Nov-20: 0.5%
- Feb-21: 0.8%
- May-21: 1.0%

Source data EU: IMS MIDAS - In-Market KPI's are based on TDx

AED market: All molecules in ATC3= N3A + Phenobarbital in NSB.
In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage.
In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
Neupro®

In-Market Performance

For patients living with
• Parkinson’s disease
• Restless legs syndrome

At its peak sales
Loss of exclusivity¹
• 2021 U.S. & EU
• 2024 Japan
• 2030 Several reformulation patents expiry (U.S. & EU)

¹ Loss of exclusivity dates are indicative.
² Numbers may not add due to rounding
Neupro® In-Market Performance

U.S.

**Neupro® PD vs. PD (KC) Market Growth (TRx)**
- PD market: -7.3%
- PD key competitors: -12.0%
- Neupro®: +1.2%

**Neupro® PD vs. (KC) Market Growth (TDx)**
- PD Market: -3.6%
- PD key competitors: -1.9%
- Neupro®: -0.8%

**Neupro® PD – R3M TRx Share**
- Neupro®: +0.3%
- 10.0%

**Neupro® PD – R3M TDx Share**
- Neupro®: 18.3%

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

Europe

**Neupro® vs. (KC) Market Growth (TDx)**
- PD Market: -3.6%
- PD key competitors: -1.9%
- Neupro®: -0.8%
- Neupro®: -2.7%

**Neupro® PD – R3M TDx Share**
- Neupro®: 34.1%

Source data EU: IMS MIDAS - In-Market KPI's are based on TDx

Japan

**Neupro® PD vs. PD (KC) Market Growth (TDx)**
- PD Market: -1.0%
- PD key competitors: -2.5%
- Neupro®: -0.4%
- Neupro®: -2.9%

**Neupro® PD – R3M TDx Share**
- Neupro®: 34.1%

Source data JP: IMS MIDAS - In-market KPI's are based on TDx

---

PD market: All molecules in ATC3= N4A. In the Europe and Japan, the TDx of all these molecules are factored for PD usage. In the US, only the TRx of Rotigotine, Pramipexole and Ropinirole are factored for PD usage. PD Key Competitors (KC) market: The 8 DA’s (Dopamine Antagonists): Bromocriptine, Cabergoline, Lisuride, Pergolide, Rotigotine, Pramipexole, Piribedil, Ropinirole

In the U.S., only Rotigotine, Pramipexole and Ropinirole are factored for PD usage, hence the PD market and PD KC market are the same.
## Our Recent Launches

### Key Information

#### Evenity®

*romosozumab*

- EU: Netherlands, Luxembourg
- Taiwan, Australia

- >100,000 patients treated since launch, currently available across 21 countries*

- Amgen (2002)

- 2031 (U.S., EU & Japan)

Evenity® is being launched globally by Amgen, Astellas and UCB since 2019, with net sales outside Europe reported by Amgen and Astellas.

#### Nayzilam®

*midazolam nasal spray*

- epilepsy seizure clusters (U.S. - 2019) – orphan disease designation

- >13,000 patients, in the U.S.

- Inlicensed from Proximagen (2018)

- 2028 (U.S.)
EVENITY® Launch Transforming the Bone Builder Market

GERMANY | Bone Builder Patient Numbers

- Teriparatide
- EVENITY® (romosozumab-aggr)

Yearly increase from 2021 HY - 18
Nayzilam®

Available to a Growing Number of Patients in the USA

For patients living with epilepsy seizure clusters (U.S. - 2019)

Nayzilam® was acquired in 2018 from Proximagen

Net sales in € million, FY numbers

1 Loss of exclusivity dates are indicative.
Accelerate & Expand (2019-2021)

News Flow

2019
- EVENITY® launch
- Nayzilam® launch (U.S.)
- bimekizumab Phase 3 results in PsO
- bimekizumab Phase 3 start in PsA & AS
- padsevonil Phase 3 start in focal-onset seizures
- rozanolixizumab Phase 3 start in MG + Phase 2a in CIDP
- Agreement to acquire Ra Pharma

2020
- rozanolixizumab Phase 3 start in ITP (Jan)
- bimekizumab Phase 3 start in HS (Feb)
- padsevonil Phase 2b topline results (March)
- Ra Pharma closing (April)
- Acquisition of Staccato® Alprazolam (June)
- Cimzia® co-promotion agreement with Ferring in the U.S. (July)
- Partnership with Roche to develop UCB0107 in AD (July)
- dapirolizumab pegol Phase 3 start in SLE (Q3)
- bimekizumab filing in PsO (Sept)
- Acquisition of Handl Therapeutics & new R&D collaboration with Lacerta Therapeutics (Nov) in gene therapy
- Vimpat® PGTCS approval (Q4)

2021
- bepranemab (UCB0107) Phase 2 started in AD (TOGETHER trial) in Q2
- EU: CHMP positive opinion on BIMZELX® (bimekizumab) in June 2021
- rozanolixizumab in CIDP de-prioritized (Feb)
- zilucoplan Phase 2 topline results in IMNM with good safety data, but C5 not relevant in this disease - discontinued
  - rozanolixizumab Phase 2 in AIE start in Q3
  - rozanolixizumab Phase 3 in MOG-antibody disease start in Q4
  - Staccato® Alprazolam Phase 3 start in active epileptic seizure in Q4
  - zilucoplan Phase 3 topline results in myasthenia gravis in Q4
  - bimekizumab Phase 3 topline results in psoriatic arthritis & axial spondyloarthritis (end of 2021)
In the following slides (slides 22-40), investigational products that are not approved for any indication by any regulatory authority in the world. Some of the investigational products require additional studies before any conclusions for safety and efficacy can be made.
Psoriasis – High Prevalence Globally

Prevalence

45% 55%

Age

Late teens–early thirties (type 1 PSO)
Fifties (type 2 PSO)

Age, geographic region, and ethnicity all influence an individual’s risk of developing PSO

Ethnicity

PSO more commonly affects Caucasians than other ethnic groups.
Prevalence according to ethnicity in the USA:

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caucasian</td>
<td>1.3%</td>
</tr>
<tr>
<td>African American</td>
<td>2.5%</td>
</tr>
</tbody>
</table>

Geographic region

Reported prevalence in adults:

<table>
<thead>
<tr>
<th>Country</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>0.91%</td>
</tr>
<tr>
<td>UK</td>
<td>2.2%</td>
</tr>
<tr>
<td>Brazil</td>
<td>2.5%</td>
</tr>
<tr>
<td>Italy</td>
<td>3.1%</td>
</tr>
<tr>
<td>France</td>
<td>5.2%</td>
</tr>
<tr>
<td>Japan</td>
<td>0.34%</td>
</tr>
<tr>
<td>Norway</td>
<td>8.5%</td>
</tr>
</tbody>
</table>

Prevalence generally increases with increasing distance from the equator.
Bimekizumab Phase 3 Clinical Development Programs

> 4,500 Patients Enrolled

- **psoriasis** (PsO)
  - > 2,000 patients
  - Filing (U.S. & EU - Sept 2020)
- **psoriatic arthritis** (PsA)
  - > 1,200 patients
  - Phase 3 ongoing
  - Topline results end 2021
- **axial spondyloarthritis** (nr AxSpA & AS)
  - > 500 patients
  - Phase 3 ongoing
  - Topline results end 2021
- **hidradenitis suppurativa** (HS)
  - ~ 1,000 patients
  - Phase 3 ongoing
  - Topline results H2 2022

Number of patients participating to the clinical programs; **bimekizumab** is an investigational product and is not approved for any indication by any regulatory authority in the world. **Bimekizumab** requires additional studies before any conclusions for safety and efficacy can be made.
# Unique Bimekizumab Phase 3 Development Program in PSORIASIS – 3x Superior to Competitors

## Phase 3

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>NCT Number</th>
<th>Topline Results</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>BE VIVID / PS0009</td>
<td>(vs ustekinumab)</td>
<td>NCT03370133</td>
<td>Positive topline results (Oct 2019)</td>
<td>Data presented @ AAD 2020</td>
</tr>
<tr>
<td>BE READY / PS0013</td>
<td>(vs placebo)</td>
<td>NCT03410992</td>
<td>Positive topline results (Nov 2019)</td>
<td></td>
</tr>
<tr>
<td>BE SURE / PS0008</td>
<td>(vs adalimumab)</td>
<td>NCT03412747</td>
<td>Positive topline results (Dec 2019)</td>
<td>EADV 2020</td>
</tr>
</tbody>
</table>

## Phase 3b

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>NCT Number</th>
<th>Topline Results</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>BE RADIANT / PS0015</td>
<td>(vs secukinumab)</td>
<td>NCT03536884</td>
<td>Positive topline results (July 2020)</td>
<td>AAD 20201 and Lancet Publication</td>
</tr>
</tbody>
</table>

Filing (US & EU - Sept 2020); positive CHMP opinion June 2021/ PDUFA date Oct 15, 2021
Psoriatic Arthritis: High Unmet Need and Disease Burden

**Psoriatic arthritis (PsA)**

PsA is a complex disease with a broad range of manifestations, including swelling of the joints, entheses, and skin psoriasis\(^1\(^-^3\). It is associated with six key disease domains\(^4\):

- Peripheral arthritis
- Axial disease
- Enthesitis
- Dactylitis
- Skin
- Nails

**Prevalence by geographic region**

<table>
<thead>
<tr>
<th>Country</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA(^14)</td>
<td>0.06–0.25%</td>
</tr>
<tr>
<td>United Kingdom(^16)</td>
<td>0.10–0.25%</td>
</tr>
<tr>
<td>France(^15)</td>
<td>0.08–0.35%</td>
</tr>
<tr>
<td>Spain(^18)</td>
<td>0.38–0.87%</td>
</tr>
<tr>
<td>Germany(^17)</td>
<td>0.18–0.25%</td>
</tr>
<tr>
<td>Italy(^15)</td>
<td>0.31–0.61%</td>
</tr>
<tr>
<td>Norway(^19)</td>
<td>0.18–0.21%</td>
</tr>
</tbody>
</table>

Global prevalence\(^13\): \(~0.13\%\)

**Disease progression**

- Up to 40% of patients with psoriasis will develop PsA\(^5,6\).
- \(~15–30\%) of patients with psoriasis have undiagnosed PsA\(^8,9\).

**Burden of disease**

- Pain/swelling\(^19\)
- Itching\(^7\)
- Depression, anxiety and mental health\(^11,20\)
- Difficulty with everyday activities\(^21\)
- Quality of life reduced\(^20,21\)

**Gender differences**

- Diagnosis is delayed\(^10\) and outcomes are worse in women\(^11,12\).
- Approximately 1 in 3 patients achieve minimal disease activity criteria in real-life studies with current treatments\(^22\).

*Based on a study of patients in cross-sectional and cohort studies (n=39) fulfilling 5 out of the 7 MDA criteria: tender joint count (TJC) ≤1; swollen joint count (SJC) ≤1; psoriasis activity and severity index (PASI) ≤1 or body surface area (BSA) ≤3; patient pain visual analogue scale (pain VAS) score ≤15; patient global disease activity (global VAS) score ≤10; health assessment questionnaire (HAQ) score ≤0.5; and tender entheseal points ≤1.

Axial Apondyloarthritis (axSpA)

Much more than just ordinary back pain

A painful chronic inflammatory disease that starts in the sacroiliac joints and progresses to the spine, ultimately causing spinal fusion in many patients over time

Patients experience disease onset before age 45, often in their 20’s. Patients typically have a delay in diagnosis of 8.5 years

Gender Prevalence

2x more common in:

- nr-axSpA women than men
- AS r-axSpA men than women

Disease Manifestations

- Uveitis: ~30%
- Psoriasis: >10%
- Inflammatory Bowel Disease: ~5–10%
- Hidradenitis Suppurativa: ~10%
- Peripheral arthritis: ~30%
- Enthesitis: ~30%
- Dactylitis: ~6%
- Psoriasis
- Inflammatory Bowel Disease
- Peripheral arthritis
- Enthesitis
- Dactylitis

Geographic prevalence

GLOBAL ~20 million people

3 KEY TREATMENTS:

- NSAIDS
- TNF inhibitors
- IL-17A inhibitors

Disease subgroups

- Chronic back pain is the main feature for all axSpA
- Up to ~60% of nr-axSpA patients will progress to AS over >10 years
- MRI inflammation of sacroiliac joints
- Structural damage of sacroiliac joints and spine

**Bimekizumab** – Ambition: Best in Disease Efficacy in Skin and Joints

Phase 3 Topline Results Expected End of 2021

### Psoriatic arthritis

**BE OPTIMAL**
- **NCT03895203**
- **PA0010**
- **840 patients**

<table>
<thead>
<tr>
<th>Week</th>
<th>Bimekizumab</th>
<th>Bimekizumab</th>
<th>Adalimumab</th>
<th>Adalimumab</th>
<th>Placebo</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Primary endpoint: ACR50 @ week 16

**BE COMPLETE**
- **NCT03896581**
- **PA0011**
- **390 patients**

<table>
<thead>
<tr>
<th>Week</th>
<th>Bimekizumab</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Primary endpoint: ASAS40 @ week 16

### Axial Spondyloarthritis

**BE MOBILE1**
- **NCT03928704**
- **AS0010**
- **240 patients**

<table>
<thead>
<tr>
<th>Week</th>
<th>Bimekizumab</th>
<th>Bimekizumab</th>
<th>Placebo</th>
<th>Bimekizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BE MOBILE2**
- **NCT03928743**
- **AS0011**
- **300 patients**

<table>
<thead>
<tr>
<th>Week</th>
<th>Bimekizumab</th>
<th>Bimekizumab</th>
<th>Placebo</th>
<th>Bimekizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BE MOBILE1**: to assess the efficacy, safety and tolerability of **bimekizumab** versus placebo in patients with active non-radiographic axial spondyloarthritis.

**BE MOBILE 2**: to assess the efficacy, safety and tolerability of **bimekizumab** versus placebo in patients with active ankylosing spondylitis.

*Bimekizumab* is an investigational product and is not approved for any indication by any regulatory authority in the world. **Bimekizumab** requires additional studies before any conclusions for safety and efficacy can be made.
Hidradenitis Suppurativa (HS): a Grim Disease

Hidradenitis suppurativa (HS)
A debilitating, chronic, inflammatory skin disease of the hair follicle that presents with painful, inflamed lesions in the armpits, genital area, groin, buttocks/anus, and breasts resulting in painful, inflamed lesions, lumps, cysts, scarring.

Prevalence
- US: ~0.10%
- Europe: ~1%
- Japan: ~0.06%
- Australia: ~0.67%

Significant delays in diagnosis ranging from 3.7–23.7 yrs.
Resulting in intense pain, progressive scarring, and psychological damage.

3x more common in women than men.

Severe Impact on QOL
- Pain
- Depression
- Anxiety
- Embarrassment
- Anger
- Disruption to Intimacy

Multiple Co-Morbidities
- Psychological Disorders
- Metabolic Syndrome
- Squamous Cell Carcinoma
- Axial Spondylo-arthritis (axSpA)
- Down Syndrome

Other Co-Morbidities
- Inflammatory Bowel Disease (IBD)
- Acne Vulgaris (AV)
- Diabetes

Affects up to 1%

GL-N-BK—2000006
**Bimekizumab: Potential New Treatment Option for HS**

**Phase 3 Topline Results H2 2022**

<table>
<thead>
<tr>
<th>Study</th>
<th>Week 16</th>
<th>Week 48</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BE HEARD I</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04242446</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
</tr>
<tr>
<td>HS0003</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
</tr>
<tr>
<td>490 patients</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
</tr>
<tr>
<td></td>
<td>placebo</td>
<td>bimekizumab</td>
</tr>
<tr>
<td><strong>BE HEARD II</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04242498</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
</tr>
<tr>
<td>HS0004</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
</tr>
<tr>
<td>490 patients</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
</tr>
<tr>
<td></td>
<td>placebo</td>
<td>bimekizumab</td>
</tr>
</tbody>
</table>

Primary endpoint: HiSCR50 @ week 16

Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.

**HS:** Hidradenitis Suppurativa; different colors for bimekizumab indicate different dosing regimens; Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

*Bimekizumab* is an investigational product and is not approved for any indication by any regulatory authority in the world. *Bimekizumab* requires additional studies before any conclusions for safety and efficacy can be made.
# Zilucoplan*: a Peptide Inhibitor in Tissue-Based C5-Mediated Diseases

<table>
<thead>
<tr>
<th>AChR+ generalized myasthenia gravis (gMG)</th>
<th>Amyotrophic lateral sclerosis (ALS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Destruction of neuromuscular junction and impaired neurotransmission secondary to autoantibody-dependent complement attack is primary mechanism of pathology in anti-AChR positive gMG&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Dysregulated complement activation and MAC proteins are associated with neuroinflammation and neurodegeneration; preclinical models support a role for C5 activation in disease</td>
</tr>
<tr>
<td>- Ptosis or diplopia occurs in 85% of patients; of those who present with ocular MG, 80% develop gMG&lt;sup&gt;4&lt;/sup&gt;</td>
<td>- Global muscle weakness&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td>- Muscle fatigue in the face, neck, arms, hands, or legs typically occurs first&lt;sup&gt;4&lt;/sup&gt; muscle weakness fluctuates: worsens with fatigue then recovers&lt;sup&gt;5&lt;/sup&gt;</td>
<td>- Respiratory problems&lt;sup&gt;10,11&lt;/sup&gt;</td>
</tr>
<tr>
<td>- Patients may experience difficulty swallowing, chewing, speaking, brushing teeth, combing hair, rising from a chair, or breathing&lt;sup&gt;5,6&lt;/sup&gt;</td>
<td>- Dysarthria and dysphagia&lt;sup&gt;10,11&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prevalence: 200 per 1 million people&lt;sup&gt;12&lt;/sup&gt;</th>
<th>Prevalence: 50-70 per 1 million people&lt;sup&gt;9&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Mestinon (Oral and IV)&lt;sup&gt;13&lt;/sup&gt;</td>
<td>- Riluzole (oral)</td>
</tr>
<tr>
<td>- Soliris (IV)</td>
<td>- Radicava (IV)</td>
</tr>
</tbody>
</table>

Zilucoplan is an investigational product and is not approved for any indication by any regulatory authority in the world. Zilucoplan requires additional studies before any conclusions for safety and efficacy can be made.

---

Zilucoplan

Zilucoplan is designed to inhibit MAC formation by a dual mechanism and allow for normal ACh signaling

• Zilucoplan is a 15-amino acid macrocyclic peptide inhibitor designed to rapidly bind and inhibit C5 cleavage (C5a and C5b)

C5-mediated diseases affect many patients living with chronic conditions

• Chronic diseases with unpredictable fluctuations and high treatment-associated burden
• Chronic, rapidly-progressing, fatal disease

<table>
<thead>
<tr>
<th></th>
<th>Proof of concept</th>
<th>Confirmatory phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generalized myasthenia gravis (MG)</td>
<td>✓</td>
<td>Topline results Q4 2021</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis (ALS)</td>
<td></td>
<td>Phase 2/3 platform trial Investigator-led study by the Healey Foundation</td>
</tr>
<tr>
<td>Immune-Mediated Necrotizing Myopathy (IMNM)</td>
<td></td>
<td>No safety issue, but hypothesis not confirmed; discontinued</td>
</tr>
<tr>
<td>COVID-associated ARDS</td>
<td></td>
<td>Investigator-led study; discontinued</td>
</tr>
</tbody>
</table>

Potential to provide a patient-focused treatment with a quick home subcutaneous infusion delivery

Zilucoplan is an investigational product and is not approved for any indication by any regulatory authority in the world. Zilucoplan requires additional studies before any conclusions for safety and efficacy can be made.
Zilucoplan Clinical Development Programs

**myasthenia gravis (MG)**

- Phase 3 ongoing
- Topline results Q4 2021
- RAISE / NCT04115293
  - 130 patients
  - 2 arms (zilucoplan vs placebo)
  - MG-ADL Score @ Week 12

**Amyotrophic lateral sclerosis (ALS)**

- Phase 2/3 platform trial
- Investigator-led study by the Healey Foundation

UCB does not comment on investigator-led studies. Please direct your questions to the Healey Foundation.

*Zilucoplan is an investigational product and is not approved for any indication by any regulatory authority in the world. Zilucoplan requires additional studies before any conclusions for safety and efficacy can be made. Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)*
**Rozanolixizumab** Potential in Multiple IgG Autoantibody-Mediated Diseases with High Unmet Medical Need

<table>
<thead>
<tr>
<th>Myasthenia gravis</th>
<th>Immune thrombocytopenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies target components of neuromuscular junction</td>
<td>Antibodies target platelets and destroy them</td>
</tr>
<tr>
<td>• Muscle weakness (extremities, eyes, bulbar and respiratory symptoms)</td>
<td>• Thrombocytopenia</td>
</tr>
<tr>
<td>• Fatigue</td>
<td>• Bleeding (petechiae, purpura, nosebleeds, intracranial bleeding)</td>
</tr>
<tr>
<td>• Fatigue</td>
<td>• Fatigue</td>
</tr>
<tr>
<td>~ 10 - 45 cases / 100 000</td>
<td>~ 10 - 50 cases / 100 000</td>
</tr>
<tr>
<td>• Surgery (thymectomy)</td>
<td>• Platelet transfusion</td>
</tr>
<tr>
<td>• Steroids, steroid-sparing drugs</td>
<td>• IV immunoglobulin (IVIg)</td>
</tr>
<tr>
<td>• Plasma exchange (PEX)</td>
<td>• Steroids</td>
</tr>
<tr>
<td>• IV immunoglobulin (IVIg)</td>
<td>• Surgery (splenectomy)</td>
</tr>
<tr>
<td></td>
<td>• TPO receptor agonists</td>
</tr>
</tbody>
</table>

**Current therapies associated with morbidity and burdensome to patients & healthcare systems**

IV: Intravenous; subQ: sub-cutaneous; TPO: thrombopoietin; **rozanolixizumab** is an investigational product and is not approved for any indication by any regulatory authority in the world. **Rozanolixizumab** requires additional studies before any conclusions for safety and efficacy can be made.
blocks FcRn receptors binding plasma IgG

Resulting in the attenuation of IgG recycling, and thus removal of IgG autoantibodies

patients living with IgG-mediated autoimmune diseases

Chronic diseases with unpredictable fluctuations and high treatment-associated burden (hospital setting, invasive)

---

<table>
<thead>
<tr>
<th>Condition</th>
<th>Proof of concept</th>
<th>Confirmatory phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>myasthenia gravis (MG)</td>
<td>✓</td>
<td>topline results Q1 2022</td>
</tr>
<tr>
<td>immune thrombocytopenia (ITP)</td>
<td>✓</td>
<td>topline results H2 2022</td>
</tr>
<tr>
<td>autoimmune encephalitis (AIE)</td>
<td>✓</td>
<td>topline results H1 2024</td>
</tr>
<tr>
<td>myelin oligodendrocyte glycoprotein (MOG)-antibody disease</td>
<td>✓</td>
<td>start Q4 2021</td>
</tr>
<tr>
<td>chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</td>
<td></td>
<td>de-prioritized (Feb 2021)</td>
</tr>
</tbody>
</table>

---

Providing a patient-focused solution with a quick home subcutaneous infusion delivery

---

1 IgG: Immunoglobulin G; Rozanolixizumab is an investigational product and is not approved for any indication by any regulatory authority in the world. Rozanolixizumab requires additional studies before any conclusions for safety and efficacy can be made.
Rozanolixizumab: Novel Targeted Approach Recycling IgG

Transforming Disease Burden for Patients

<table>
<thead>
<tr>
<th>Condition</th>
<th>Phase Status</th>
<th>Topline Results</th>
<th>Study Identification</th>
<th>Patient Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myasthenia Gravis (MG)</td>
<td>Phase 3 ongoing</td>
<td>Q1 2022</td>
<td>MG0003 / NCT03971422</td>
<td>240 patients 3 arms (rozanolixizumab vs. placebo) MG-ADL Score @ Day 43</td>
</tr>
<tr>
<td>Immune Thrombocytopenia (ITP)</td>
<td>Phase 3 ongoing</td>
<td>H2 2022</td>
<td>TP0003 / NCT04200456</td>
<td>105 patients 2 arms (rozanolixizumab vs. placebo) Platelet Response of ≥50x10^9/L during weeks 13-25</td>
</tr>
<tr>
<td>Autoimmune Encephalitis (AIE)</td>
<td>Phase 2 to start in Q3 2021</td>
<td>H1 2024</td>
<td>AIE001 / NCT04875975</td>
<td>68 patients 2 arms (rozanolixizumab vs. placebo) Seizure freedom during 24 weeks</td>
</tr>
<tr>
<td>Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease</td>
<td>Phase 3 to start in Q4 2021</td>
<td>Not yet registered</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: www.clinicaltrial.gov; MG-ADL : Myasthenia Gravis-Activities of Daily Living; iRODS : inflammatory Rasch-built Overall Disability Scale; rozanolixizumab is an investigational product and is not approved for any indication by any regulatory authority in the world. Rozanolixizumab requires additional studies before any conclusions for safety and efficacy can be made.
Systemic Lupus Erythematosus (SLE)

Inflammation in Many Organ Systems Simultaneously or Sequentially

Systemic Lupus Erythematosus (SLE) is a disease of flares and remissions, with symptoms that can include:
- Facial or other rashes
- Joint pain, stiffness and swelling
- Headaches, confusion, memory loss

Symptoms vary by individual
Range from fatigue, joint pain, butterfly shaped skin rash across the face, fever, weight/ hair loss, and photosensitivity

Systemic Lupus Erythematosus (SLE) affects more than 5 million people globally, the majority of whom are women of child-bearing age.

Lupus predominantly affects women¹
- 80-90% of cases between 15 – 45
- Disproportionately affects women of colour²

Opportunity to focus on the underserved patient population
- minorities who often have more severe disease
- underrepresented in clinical research
- may experience unique challenges accessing health care

More about lupus on https://www.ucb.com/disease-areas/Lupus;⁴ Source: https://www.lupus.org/resources/what-is-lupus accessed 19 November 2020; ²African American, Hispanic and Native American. Women; dapirolizumab pegol is an investigational product and is not approved for any indication by any regulatory authority in the world. dapirolizumab pegol requires additional studies before any conclusions for safety and efficacy can be made.
Dapirolizumab Pegol Clinical Development Program

Dapirolizumab pegol

- CD 40L
- 50/50 partnership with Biogen (2003)

Systemic Lupus Erythematosus (SLE)

Phase 3 ongoing
Topline results H1 2024

NCT04294667 / SL0043 / PHOENYCS GO
450 patients
2 arms (dapirolizumab pegol vs placebo)
BICLA response @ Week 48

Source: [www.clinicaltrial.gov](http://www.clinicaltrial.gov); BICLA: BILAG 2004-based Composite Lupus Assessment; dapirolizumab pegol is an investigational product and is not approved for any indication by any regulatory authority in the world. dapirolizumab pegol requires additional studies before any conclusions for safety and efficacy can be made.
**Acute On-Demand Epilepsy Seizure Management**

Developing **Staccato® Alprazolam** for the Rapid Termination of Epileptic Seizures

**Staccato® Alprazolam**, a drug-device-combination designed to deliver *alprazolam* with a single, normal breath, to rapidly terminate an epileptic seizures.

- Potential to be the first on-demand, single use treatment
- **Rapid seizure termination** (30 sec – 2 min)
- Phase 2b clinical trial completed (end 2019); phase 3 to start Q4 2021
- Potential to deliver on-demand, rapid seizure termination for 20 – 30% of people living with epilepsy

**UCB** to perform further clinical development, submission, launch and commercialization

---

Staccato® Alprazolam is an investigational product and is not approved for any indication by any regulatory authority in the world. Staccato® Alprazolam requires additional studies before any conclusions for safety and efficacy can be made.
**Bepranemab (UCB0107), our Anti-Tau Antibody**

Phase 2 in Alzheimer’s Disease (AD) Started in Q2 2021

- **Protein Tau misfolding & aggregation** leads to nerve cell death & disease spread in the brain. AD is also a tauopathy, with high prevalence and economic impact/burden.

- Bepranemab is a recombinant, humanized, full-length immunoglobulin G4 monoclonal antibody that binds to a central tau epitope (amino acids 235–250). Bepranemab is being developed to **block or reduce the spread of tau pathology** in people living with tau-mediated diseases, like AD. Developed in-house in Braine-l'Alleud (Belgium).

- **Bepranemab (UCB0107)** is in clinical development for people living with AD.

- AH0003 (TOGETHER trial) is a global, multicentre, double-blind, placebo controlled, parallel-group Phase 2 study, designed to investigate the efficacy, safety, and tolerability of bepranemab (intravenously, every 4 weeks) versus placebo in patients with prodromal (40%) or mild (60%) AD over an 80-week treatment period, followed by an optional 48-week open-label extension (OLE) treatment period.

- In partnership with Genentech / Roche

---

1 Courade J-P et al. Acta Neuropathol. 2018;136:729–45; bepranemab is an investigational product and is not approved for any indication by any regulatory authority in the world. Bepranemab requires additional studies before any conclusions for safety and efficacy can be made.
Solid Cash Flow

Cash flow from continuing operations

<table>
<thead>
<tr>
<th>Year</th>
<th>€ million</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016 FY</td>
<td>726</td>
</tr>
<tr>
<td>2017 FY</td>
<td>896</td>
</tr>
<tr>
<td>2018 FY</td>
<td>1,098</td>
</tr>
<tr>
<td>2019 FY</td>
<td>893</td>
</tr>
<tr>
<td>2020 FY</td>
<td>1,092</td>
</tr>
</tbody>
</table>

CAGR +9%

Net debt / adjusted EBITDA ratio

<table>
<thead>
<tr>
<th>Year</th>
<th>€ million</th>
<th>Net cash</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016 FY</td>
<td>838</td>
<td>0.81</td>
</tr>
<tr>
<td>2017 FY</td>
<td>525</td>
<td>0.38</td>
</tr>
<tr>
<td>2018 FY</td>
<td>237</td>
<td>0.17</td>
</tr>
<tr>
<td>2019 FY</td>
<td></td>
<td>-0.01</td>
</tr>
<tr>
<td>2020 FY</td>
<td>1,411</td>
<td>0.98</td>
</tr>
</tbody>
</table>

EBITDA: Earning before interests, taxes, depreciation and amortization charges - In compliance with the ESMA Alternative Performance Measures guidelines, recurring EBITDA, is renamed into "adjusted EBITDA". The calculation methodology remains unchanged.
Debt Maturity Schedule (@ 31 July 2021, € million)
UCB New Organization

Our People are Key to Deliver on our Ambition

8,371* employees worldwide

* Situation at 31 December 2020
CEO office consists of department reporting directly to the CEO including the Sustainability team and the Internal Audit team

FUNCTIONS
- Corporate Development & Finance - 386
- Legal & Risk - 148
- Talent & Company Reputation - 227

SOLUTIONS
- Early Solutions 723
- Development Solutions 1061
- Immunology Solutions 1262
- Neurology Solutions 2111
- Supply & Technology Solutions 2439

* Situation at 31 December 2020
CEO office consists of department reporting directly to the CEO including the Sustainability team and the Internal Audit team
One UCB today: a Global Player

Presence in 38 Countries Complemented by a Robust Network of Partners

8 371* employees worldwide

50/50 Women / Men

1 436 New colleagues

8% Employee turnover

*Situation at 31 December 2020
For more details about UCB employees, refer to UCB 2020 integrated annual report
We See Sustainability as an Approach for Business Growth and Societal Impact

We aim to bring to patients differentiated solutions with higher predictability of response and in 2030, all patients who need these solutions shall have access to them in a way which is viable for patients, society and UCB.

By 2030, we will be carbon neutral and we will have reduced our water consumption and waste production by respectively 20% and 25%.

By 2025, we will lead in 5 specific patient populations.

Our revenue are expected to reach of at least € 6 billion and our adj. EBITDA margin to be in the low to mid-thirties.

We will have improved significantly our ESG rating performance.
...Continuing to Advance on Our Sustainable Growth Journey

Long Term Objectives

Value for patients
Progressing on our Access Performance Index:
+ NAZYLAM®
+ new countries to reach a total of 25 countries

Exploring new business models for epilepsy in India: pilot ready to start in Q4/2021 to test a social business prototype

Value for people at UCB and our communities
Hybrid working model announced

Avid Employee Resources Group launched for employees living with a health condition, a disability or those who are care-givers

Health Safety and Wellbeing index update year-end

DE&I index under development

UCB Community Health Fund: 2nd call for projects

Value the planet
-23.7% vs. -3%* as year end target for emissions from energy consumptions and goods distribution

-96% vs. -40%** as year-end target for business travel

15% vs. 15% as year-end target for suppliers (by emissions)

Value for shareholders

UCB ESG Sustainalytics rating improved to low risk (16.7) from medium risk (25.4)

* Baseline 2020
** Baseline 2019
UCB Green Strategy

Our Environmental Targets by 2030

CO₂ emissions
- 35%

Water consumption
- 20%

Waste production
- 25%

KPIs at 31 December 2020
For more details about UCB environmental footprint, refer to UCB 2020 integrated annual report
Corporate Governance

Board of Directors

- 14 members
  - Mandate: 4 year
  - Age limit: 70
- 5 women (36%)
- 9 independent directors (64%)
- 7 nationalities

Status at June 2021

For more details about diversity @ Board level, refer to UCB 2020 integrated annual report
Corporate Governance

Executive Committee

- 9 members
  - Jean-Christophe Tellier, CEO since 2015
- 3 women (33%)
- 5 nationalities

For more details about diversity at ExCom level, refer to UCB 2020 integrated annual report
Corporate Governance

Executive Committee Headed by Jean-Christoph Tellier

- 9 members
- 3 women (33%)
- 5 nationalities

JC Tellier, CEO
D. Patel, CSO
I. Löw-Friedrich, CMO
K. Lund-Jurgensen, Supply & Technology Solutions
C. van Zyl, Neurology Solutions & Head of EU / International

JL Fleurial, CHRO
S. Dufour, CFO
B. Silbey, General Counsel
E. Caeymaex, Immunology Solutions & Head of U.S
Shareholder identification January 2021

Institutional Investors: Geographic distribution

- United States: 51%
- United Kingdom: 18%
- France: 7%
- Belgium: 5%
- Rest of Europe: 15%
- Rest of World: 4%

Institutional Investors: Investment style

- Value: 31%
- Growth: 23%
- Index: 1%
- GARP: 14%
- Hedge: 2%
- Other: 9%

Source: Latest notifications and shareholder identification (as of January 2021), UCB underlying ownership analysis
UCB China: a Fast-Growing Biopharma Company

Everything we do starts with one simple question:
How will this create value for people living with severe diseases?
UCB: a Strong Presence in China

Starting Pharmaceutical Business Operations in China in 1996

- 7 clinical trials in initiation/ongoing
- >500 employees
- >500,000 patients served annually
- 4 new molecule entities potentially by 2025
- 4 new molecule entities potentially by 2025

- UCB: a Strong Presence in China
- Starting Pharmaceutical Business Operations in China in 1996
Bringing Innovative Medicines to China

UCB Products in China

From 2008 through 2021, 3 new products, 2 new formulations and 10 indications approved in China

*RA = rheumatoid arthritis
Innovate for Chronic Disease Management and Accelerate Digital Transformation through Partnerships

With Ali Health

With JD Health

With Cinkate

With Tecent Health
Corporate Societal Responsibilities in China

**Rainbow Bridge**
- Partnership with Project HOPE & Shanghai Children’s Medical Center
- Medical education
- Raise awareness on epilepsy in schools and communities
- Activities for patients & families

**UCB Health & Hope Fund**
- Partnership with Business Development Center of Red Cross Society of China
- Comprehensive training program for village doctors
- Epilepsy Assistance Program (Pilot in Zigong)

**Brain Science Education Special Fund**
- Partnership with the Shanghai Science and Technology Museum (SSTM) and the Shanghai Science Education Development Foundation (SSEDF)
- The first Brain Science Education Special Fund in China
- Establishment of brain science educational platforms and support for public education programs of brain science
UCB Investor Relations Team

Antje Witte
Head of Investor Relations
Phone: +32 2 559 9414
E-mail: antje.witte@ucb.com

Julien Bayet
Investor Relations Manager
Phone: +32 2 559 9580
E-mail: julien.bayet@ucb.com

Alex Klein
Investor Relations Lead
Phone: +32 2 559 9948
E-mail: alex.klein@ucb.com

Check out our IR App &
connect to UCB wherever you go!